Update on hepatitis C: Direct-acting antivirals

World Journal of Hepatology

Volumn 7, Issue 28, 2015, Pages 2829-2833

  Seifert, Leon L ^a   Perumpail, Ryan B ^b   Ahmed, Aijaz ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct acting antivirals; Hepatitis C virus; Management; Sustained virologic response; Treatment

Indexed keywords

EID: 84949561087     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i28.2829     Document Type: Review

References (44)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562 DOI: 10.1126/science.2523562]
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
3. Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011; 10: 659-672 [PMID: 21604986 DOI: 10.1586/erv.11.55]
4. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87 [PMID: 25069599 DOI: 10.1002/hep.27259]
5. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31 Suppl 1: 9-16 [PMID: 10622554 DOI: 10.1016/S 0168-8278(99)80368-7]
6. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52 [PMID: 11439948 DOI: 10.1056/NEJM200107053450107]
7. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev Med Virol 2003; 13: 57-68 [PMID: 12516062 DOI: 10.1002/rmv.371]
8. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-1605 [PMID: 25078304 DOI: 10.1016/S0140-6736(14)61059-X]
9. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142.e4 [PMID: 24704719 DOI: 10.1053/j.gastro.2014.03.051]
10. Lindenbach BD, Murray CL, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In DM Knipe and PM Howley (editors). Fields virology, 6th ed. Lippincott Williams&Wilkins: New York, NY, 2013
11. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645]
12. Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM. Studying hepatitis C virus: making the best of a bad virus. J Virol 2007; 81: 8853-8867 [PMID: 17522203 DOI: 10.1128/JVI.00753-07]
13. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974 [PMID: 11110665 DOI: 10.1126/science.290.5498.1972]
14. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113 [PMID: 10390360 DOI: 10.1126/science.285.5424.110]
15. Wölk B, Büchele B, Moradpour D, Rice CM. A dynamic view of hepatitis C virus replication complexes. J Virol 2008; 82: 10519-10531 [PMID: 18715913 DOI: 10.1128/JVI.00640-08]
16. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-1998 [PMID: 17484890 DOI: 10.1053/j.gastro.2007.03.116]
17. Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, Barreiro P. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011; 66: 1673-1686 [PMID: 21652618 DOI: 10.1093/jac/dkr215]
18. Sofia MJ. Nucleotide prodrugs for the treatment of HCV infection. Adv Pharmacol 2013; 67: 39-73 [PMID: 23885998 DOI: 10.1016/B978-0-12-405880-4.00002-0]
19. Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Nájera I. Existence of hepatitis C virus NS5B variants naturally resistant to nonnucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008; 61: 1205-1216 [PMID: 18343801 DOI: 10.1093/jac/dkn085]
20. Gane EJ, Hyland RH, An D, Svarovskaia ES, Pang PS, Symonds WT, McHutchinson JG, Stedman CA. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. AASLD, Boston, MA, USA, 2014: Abstract LB-11
21. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-487 [PMID: 24387618 DOI: 10.1111/apt.12601]
22. Appel N, Schaller T, Penin F, Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 2006; 281: 9833-9836 [PMID: 16407182 DOI: 10.1074/jbc.R500026200]
23. He Y, Staschke KA, Tan SL. HCV NS5A: a multifunctional regulator of cellular pathway and virus replication. In Hepatitis C Viruses. In: Tan SL, editor. SourceHepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience, 2006: Chapter 9 [PMID: 21250384]
24. Szabo G. Hepatitis C virus NS5A protein--a master regulator? Gastroenterology 2006; 130: 995-999 [PMID: 16530536 DOI: 10.1053/j.gastro.2006.01.072]
25. Huang Y, Staschke K, De Francesco R, Tan SL. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 2007; 364: 1-9 [PMID: 17400273 DOI: 10.1016/j.virol.2007.01.042]
26. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015; 42: 559-573 [PMID: 26113432 DOI: 10.1111/apt.13300]
27. Höner Zu Siederdissen C, Maasoumy B, Deterding K, Port K, Sollik L, Mix C, Kirschner J, Cornberg J, Manns MP, Wedemeyer H, Cornberg M. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver Int 2015; 35: 1845-1852 [PMID: 25556625 DOI: 10.1111/liv.12774]
28. Dieterich D, Bacon BR, Flamm SL, Kowdley KV, Milligan S, Tsai N, Younossi ZM, Lawitz E. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. 65th Annual Meeting of the American Association for the Study of Liver diseases. Boston, USA, 2014: Abstract 46
29. Jensen DM, O'Leary JG, Pockros PJ, Sherman KE, Kwo PY, Mailliard ME, Kowdley KV, Muir AJ, Dickson RC, Ramani A, Manns MP, Lok AS, Akuskevich L, Nelson DR, Fried MW. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. 65th Annual Meeting of the American Association for the Study of Liver diseases. Boston, USA, 2015: Abstract 45
30. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603 [PMID: 24720703 DOI: 10.1056/NEJMoa1315722]
31. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]
32. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology 2015; 61: 1798-1808 [PMID: 25627448 DOI: 10.1002/hep.27724]
33. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493 [PMID: 24725238]
34. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898 [PMID: 24725239]
35. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]
36. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765 [PMID: 25078309]
37. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
38. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-2091 [PMID: 24604476 DOI: 10.1002/hep.27113]
39. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]
40. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014; 21: 762-768 [PMID: 25196837 DOI: 10.1111/jvh.12312]
41. Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, McHutchison JG, Stedman CA. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014; 60: S1-S22 [DOI: 10.1016/S0168-8278(14)60008-8]
42. Ruane PJ, Ain D, Meshrekey R, Riad J, Stryker R, Soliman M, Mikhail S, Wolfe PR, Kersey K, Doehle B, Deyuan J, Symonds WT. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. J Hepatol 2014; 60: S503-S504 [DOI: 10.1016/S0168-8278(14)61403-3]
43. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-954 [PMID: 26111063 DOI: 10.1002/hep.27950]
44. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236 [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025]